Schayowitz Adam sold $358K of ZYME
Schayowitz Adam (EVP, Head of R&D) sold 13,832 shares of Zymeworks Inc. (ZYME) at $25.85 ($0.36M total) on 2026-10-09.
How this was made
The 30-second read
Why it matters
This disclosure updates the insider-trading record and may influence sentiment, but it does not introduce new company fundamentals such as trial results, guidance, or financing terms.
Market read
Traders may briefly reassess sentiment around ZYME due to insider selling, but the filing alone is unlikely to drive a major repricing without additional catalysts.
What to watch
No context is provided on prior insider activity, option exercises, or whether the executive’s remaining holdings are subject to other planned transactions.
Background
The article is an SEC Form 4 insider transaction for Zymeworks Inc., reporting an open-market sale by an EVP in R&D.
Ticker impact
Zymeworks EVP Head of R&D Adam Schayowitz sold 13,832 shares on 2026-10-09 at $25.85, totaling about $357.6K, per Form 4.
Likely limited, short-lived pressure as traders weigh the insider sale against broader fundamentals.
The filing is a primary SEC Form 4 disclosure, but the dollar amount is relatively small versus typical institutional flows and the article provides no accompanying company-specific operational or guidance catalyst.
Market effects
Minimal, as this is a single-company insider transaction with no stated sector-wide regulatory or clinical catalyst.
None indicated; the disclosure is company-specific.
None indicated; no cross-border deal, trial, or regulatory action is described.
Counterpoint
The sale could be routine liquidity management or tax-related, and the absence of a 10b5-1 plan in the text does not prove bearish intent.
Key entities
- issuerZymeworks Inc.
Biopharma company whose Form 4 reports an insider open-market sale by its EVP Head of R&D.
- insiderSchayowitz Adam
EVP, Head of R&D who sold 13,832 shares on 2026-10-09.
